PC
MRVI icon

Pier Capital’s Maravai LifeSciences MRVI Stock Holding History

Pier Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,127,773
Closed -$6.15M – 123
2024
Q4 		$6.15M Buy
1,127,773
+651,921
+137% +$4.19M 0.88% 71
2024
Q3 		$3.95M Sell
475,852
-2,503
-0.5% -$21.6K 0.56% 93
2024
Q2 		$3.43M Sell
478,355
-27,940
-6% -$241K 0.51% 90
2024
Q1 		$4.39M Buy
506,295
+219,446
+77% +$1.48M 0.6% 77
2023
Q4 		$1.88M Sell
286,849
-3,714
-1% -$24K 0.27% 93
2023
Q3 		$2.91M Sell
290,563
-5,487
-2% -$60.3K 0.47% 88
2023
Q2 		$3.68M Sell
296,050
-5,298
-2% -$71.5K 0.53% 90
2023
Q1 		$4.22M Buy
301,348
+29,193
+11% +$419K 0.64% 78
2022
Q4 		$3.89M Buy
272,155
+254,314
+1,425% +$4M 0.64% 76
2022
Q3 		$455K Sell
17,841
-13,785
-44% -$346K 0.08% 96
2022
Q2 		$898K Buy
31,626
+12,244
+63% +$388K 0.15% 90
2022
Q1 		$684K Buy
19,382
+9,014
+87% +$302K 0.09% 98
2021
Q4 		$434K Buy
+10,368
New +$420K 0.05% 107

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pier Capital's MRVI Position: Q1 2025 in Review

Pier Capital sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 1,127,773 shares — an estimated $6.15M sold.

Pier Capital first reported a position in MRVI in Q4 2021 and held it in 13 quarters. The position peaked at $6.15M in Q4 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • Pier Capital reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
  • Pier Capital sold 1,127,773 Maravai LifeSciences shares in Q1 2025, an estimated $6.15M.
  • Pier Capital first reported a position in Maravai LifeSciences in Q4 2021 and held it in 13 quarters.
  • Pier Capital's Maravai LifeSciences position peaked at $6.15M in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Pier Capital's 13F filing for Q1 2025, filed 13 May 2025.